Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects - Tang, Kai-Yang; Lickliter, Jason; Huang, Zhi-Hua; Xian, Zong-Shu; Chen, Han-Yang; Huang, Cheng; Xiao, Chong; Wang, Yu-Peng; Tan, Ying; Xu, Lin-Feng; Huang, Yu-Liang; Yan, Xiao-Qiang (Cellular & molecular immunology, 2019)
Keywords: Adult; Amyloid; Antibodies; Bacterial Infections - drug therapy; Biomarkers; Biomarkers - blood; Biomedical and Life Sciences; Biomedicine; C-reactive protein; Chemokines; Clinical trials; Constant region; Cytokines; Cytokines - blood; Dimerization; Dosage; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fusion protein; Healthy Volunteers; Humans; Immunoglobulin Constant Regions - genetics; Immunoglobulin G; Immunology; Inflammation Mediators - blood; Inflammatory diseases; Infusions, Intravenous; Injection; Injection Site Reaction - etiology; Interleukin 22; Interleukins - genetics; Intravenous administration; Male; Medical Microbiology; Microbiology; Pharmacodynamics; Pharmacokinetics; Recombinant Fusion Proteins - adverse effects; Recombinant Fusion Proteins - pharmacokinetics; Recombinant Fusion Proteins - therapeutic use; Serum Amyloid A Protein - metabolism; Serum levels; Skin; Triglycerides; Vaccine; Wound Healing - drug effects; Young Adult; Pharmacodynamics; F-652; Safety; Pharmacokinetics; Interleukin-22